Lisata Therapeutics, Inc. Common Stock
Here’s whether Lisata Therapeutics, Inc. Common Stock (LSTA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-15.78% over 10 days); RSI 76 — overbought, elevated pullback risk; weak 1-year return of -37.2%; 3-month momentum negative (-50.6%); rising volume on a downtrend (distribution, 2.23x avg). Currently 69.4% off its 52-week high. Score: -7/7.
LSTA is trading below its 200-day MA ($3.15) — a key warning sign the longer-term trend is under pressure. With an RSI of 75.8, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -37.3% compares to +20.5% for SPY (trailed the market by 57.7%). The current 69.4% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.